Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Treatment regimen

Amivantamab with lazertinib (MARIPOSA)

First line in EGFR-mutant lung cancer; weight-based dosing and thrombosis prevention

Updated: 28 October 20261 min read3 references

Summary for doctors

  • Advanced lung cancer with exon 19 deletion or L858R, first line [1].
  • Prophylactic anticoagulation is needed for the first 4 months [2].
  • Infusion reactions with the first dose and skin toxicity are common [1].

Dose and schedule

Amivantamab + lazertinib

Advanced EGFR-positive lung cancerEach drug’s schedule in the table

Advanced EGFR-positive lung cancer

DrugDoseRouteSchedule
Lazertinib240 mg once a dayOralDaily
Amivantamab (weight below 80 kg)1050 mgIVWeekly in weeks 1 to 5 (first dose split over days 1 and 2), then every 2 weeks from week 7
Amivantamab (weight 80 kg or more)1400 mgIVSame schedule
Cycle schedule
Lazertinib daily; amivantamab weekly, then every 2 weeks
Duration
Until progression

As in MARIPOSA [1]; dose source: [2, 3].

Evidence: MARIPOSA (2024)

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Premedication and supportive care

  • Premedication before each infusion (antihistamine, antipyretic and, for the first doses, a steroid).
  • Prophylactic anticoagulation (for example apixaban or rivaroxaban at a prophylactic dose) for the first 4 months [2].
  • Skin prophylaxis: doxycycline or minocycline, moisturising cream and sunscreen.

Monitoring and dose adjustment

  • Infusion reactions, rash and paronychia, oedema, ILD and venous thrombosis [2]; blood counts and liver enzymes.

Main evidence

Show detailsHide

MARIPOSA: median progression-free survival 23.7 vs 16.6 months with osimertinib [1].

Related cancer types

Lung cancer

Treatment regimens (physicians)

Trastuzumab deruxtecan (T-DXd, Enhertu): dose and monitoringCarboplatin, pemetrexed and pembrolizumab (KEYNOTE-189)Carboplatin, paclitaxel and pembrolizumab (KEYNOTE-407)Carboplatin-etoposide with atezolizumab or durvalumab in small cell lung cancerDurvalumab after chemoradiotherapy in stage 3 lung cancer (PACIFIC)Pembrolizumab alone in lung cancer with high PD-L1 (KEYNOTE-024)Osimertinib with pemetrexed and platinum (FLAURA2)Adjuvant alectinib after surgery for ALK-positive lung cancer (ALINA)

Physician tools and lessons

Khorana Score (Cancer-Associated Thrombosis Risk)Should I Be Screened for Lung Cancer? (Pack-Year Calculator)10 cheap steps that save patients' livesManagement of brain metastasesMalignant pleural effusion: drainage, pleurodesis or an indwelling catheter

References

3 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLCCho BC, Lu S, Felip E, et al · N Engl J Med · 2024;391:1486-1498
    Study cardDOIPubMed Back to text: 1 2 3 4
  2. 2
    RYBREVANT (AMIVANTAMAB-VMJW) — Prescribing InformationJanssen Biotech, Inc · FDA label · 2026
    Source Back to text: 1 2 3 4
  3. 3
    LAZCLUZE (LAZERTINIB) — Prescribing InformationJanssen Biotech, Inc · FDA label · 2026
    Source Back to text

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/amivantamab-lazertinib/

Related pages

27 October 2026 FOLFOX (mFOLFOX6): dose, schedule and side effects Dose and schedule of mFOLFOX6 (oxaliplatin 85, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), length of adjuvant treatment, premedication, neuropathy and dose adjustment. 27 October 2026 CAPOX (XELOX): dose, schedule and side effects Dose and schedule of CAPOX or XELOX (oxaliplatin 130 and capecitabine 1000 twice daily, days 1 to 14), length of adjuvant treatment, renal adjustment and side effects. 27 October 2026 FOLFIRI regimen: dose, schedule and side effects Dose and schedule of FOLFIRI (irinotecan 180, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), diarrhoea control, UGT1A1 and dose adjustment.